AI can turn complex protocols into first-pass budget inputs, letting sponsors start budgeting sooner while budget builders shift from data entry to review.
|Articles|March 31, 2015
PAREXEL Launches LIQUENT InSight 6.0
PAREXEL introduced the latest version of its Regulatory Information Management (RIM) platform: LIQUENT InSight® 6.0
Advertisement
PAREXEL introduced the latest version of its Regulatory Information Management (RIM) platform: LIQUENT InSight® 6.0. The LIQUENT InSight platform supports the entire regulatory product lifecycle, from early planning of registration targets through product retirement.
Specific enhancements to this version include the following:
- Business Intelligence: added analytics to enhance reporting capabilities
- Usability: simplified interface for all experience to all levels of InSight user
- Compliance: updated data model and compliance with standards such as XEVMPD and the upcoming IDMP mandate
- Interoperability: revamped features that help systems interact and communicate with each other
Advertisement
Related to this article
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
In this video interview, Carole Berini, PhD, of Ontada, explains how validated proxies for variables like ECOG performance status can recover not just sample size but the representativeness of hard-to-reach patient populations in real-world oncology studies.
A biomarker test now decides who enters a precision medicine trial, yet results often go unused and assays are not ready when screening opens.
In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.
Real-time RBQM requires proportionate analysis frequency matched to data arrival and issue criticality, not continuous reanalysis, because signal churn from over-frequent runs creates alert fatigue and operational noise that obscures meaningful deterioration.
In this video interview, Saamir Pasha and Carole Berini, PhD, of Ontada, explain how building trust into the data foundation—through source lineage, standardization, and reconciliation—is what makes reliable real-world evidence generation in oncology possible.
In today's ACT Brief, we examine how AI surfaces design flaws before enrollment, why site training readiness depends on learning science, and the priorities defining next-generation weight-loss therapies.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
AI and Patient Recruitment: Can Predictive Promise Drive True Transformation?
2
Better Site Training Starts With Five Simple Questions
3
Start Study Budgets Sooner With AI-Enabled Protocol Translation
4
How Routine Lab Markers Can Stand In for Missing Functional Status Data
5